Published in Neurotherapeutics on January 01, 2015
Ubiquilin-2 drives NF-κB activity and cytosolic TDP-43 aggregation in neuronal cells. Mol Brain (2015) 0.77
Stress granules at the intersection of autophagy and ALS. Brain Res (2016) 0.75
Withania somnifera Reverses Transactive Response DNA Binding Protein 43 Proteinopathy in a Mouse Model of Amyotrophic Lateral Sclerosis/Frontotemporal Lobar Degeneration. Neurotherapeutics (2016) 0.75
Differential effects of phytotherapic preparations in the hSOD1 Drosophila melanogaster model of ALS. Sci Rep (2017) 0.75
Current Therapy of Drugs in Amyotrophic Lateral Sclerosis. Curr Neuropharmacol (2016) 0.75
HSPB1 mutations causing hereditary neuropathy in humans disrupt non-cell autonomous protection of motor neurons. Exp Neurol (2017) 0.75
The heat shock response in neurons and astroglia and its role in neurodegenerative diseases. Mol Neurodegener (2017) 0.75
Administration of 17β-Estradiol Improves Motoneuron Survival and Down-regulates Inflammasome Activation in Male SOD1(G93A) ALS Mice. Mol Neurobiol (2016) 0.75
Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science (2006) 27.96
Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature (1993) 21.65
Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science (1994) 18.08
TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science (2008) 14.09
TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun (2006) 10.69
TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat Genet (2008) 9.51
TDP-43 A315T mutation in familial motor neuron disease. Ann Neurol (2008) 5.58
TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. Lancet Neurol (2008) 5.33
Activation of heat shock gene transcription by heat shock factor 1 involves oligomerization, acquisition of DNA-binding activity, and nuclear localization and can occur in the absence of stress. Mol Cell Biol (1993) 5.11
Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases. Neuron (2001) 4.43
Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS. Nat Neurosci (2010) 4.25
Scientific basis for the therapeutic use of Withania somnifera (ashwagandha): a review. Altern Med Rev (2000) 4.11
Selective ablation of proliferating microglial cells exacerbates ischemic injury in the brain. J Neurosci (2007) 3.93
A role for motoneuron subtype-selective ER stress in disease manifestations of FALS mice. Nat Neurosci (2009) 3.89
Chromogranin-mediated secretion of mutant superoxide dismutase proteins linked to amyotrophic lateral sclerosis. Nat Neurosci (2005) 3.69
Epidemiology of mutations in superoxide dismutase in amyotrophic lateral sclerosis. Ann Neurol (1997) 2.84
Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. Glia (1998) 2.82
A rapid, simple, and humane method for submandibular bleeding of mice using a lancet. Lab Anim (NY) (2005) 2.78
CD4+ T cells support glial neuroprotection, slow disease progression, and modify glial morphology in an animal model of inherited ALS. Proc Natl Acad Sci U S A (2008) 2.72
T lymphocytes potentiate endogenous neuroprotective inflammation in a mouse model of ALS. Proc Natl Acad Sci U S A (2008) 2.26
High frequency of TARDBP gene mutations in Italian patients with amyotrophic lateral sclerosis. Hum Mutat (2009) 2.05
Contribution of TARDBP mutations to sporadic amyotrophic lateral sclerosis. J Med Genet (2008) 2.00
Withaferin a strongly elicits IkappaB kinase beta hyperphosphorylation concomitant with potent inhibition of its kinase activity. J Biol Chem (2006) 1.91
Novel antibodies reveal inclusions containing non-native SOD1 in sporadic ALS patients. PLoS One (2010) 1.89
Neuroprotection through excitability and mTOR required in ALS motoneurons to delay disease and extend survival. Neuron (2013) 1.87
Oxidative stress in ALS: key role in motor neuron injury and therapeutic target. Free Radic Biol Med (2009) 1.82
Adaptive immune neuroprotection in G93A-SOD1 amyotrophic lateral sclerosis mice. PLoS One (2008) 1.65
Systemically administered interleukin-10 reduces tumor necrosis factor-alpha production and significantly improves functional recovery following traumatic spinal cord injury in rats. J Neurotrauma (1999) 1.55
Neuroprotection by IL-10-producing MOG CD4+ T cells following ischemic stroke. J Neurol Sci (2005) 1.54
Aggregation of copper-zinc superoxide dismutase in familial and sporadic ALS. Antioxid Redox Signal (2009) 1.52
Message and protein-level elevation of tumor necrosis factor alpha (TNF alpha) and TNF alpha-modulating cytokines in spinal cords of the G93A-SOD1 mouse model for amyotrophic lateral sclerosis. Neurobiol Dis (2003) 1.51
Intracerebroventricular infusion of monoclonal antibody or its derived Fab fragment against misfolded forms of SOD1 mutant delays mortality in a mouse model of ALS. J Neurochem (2010) 1.47
Hsp27 upregulation and phosphorylation is required for injured sensory and motor neuron survival. Neuron (2002) 1.46
Deregulation of TDP-43 in amyotrophic lateral sclerosis triggers nuclear factor κB-mediated pathogenic pathways. J Exp Med (2011) 1.46
Microglia induce motor neuron death via the classical NF-κB pathway in amyotrophic lateral sclerosis. Neuron (2014) 1.44
Aberrant localization of FUS and TDP43 is associated with misfolding of SOD1 in amyotrophic lateral sclerosis. PLoS One (2012) 1.42
Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival. EMBO Mol Med (2012) 1.42
From transcriptome analysis to therapeutic anti-CD40L treatment in the SOD1 model of amyotrophic lateral sclerosis. Nat Genet (2010) 1.32
Cytokine upregulation in a murine model of familial amyotrophic lateral sclerosis. Brain Res Mol Brain Res (2001) 1.32
Reactions of the immune system in chronic degenerative neurological diseases. Can J Neurol Sci (1991) 1.29
Immune system alterations in sporadic amyotrophic lateral sclerosis patients suggest an ongoing neuroinflammatory process. J Neuroimmunol (2009) 1.28
Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid. Mult Scler (2009) 1.27
Withania somnifera reverses Alzheimer's disease pathology by enhancing low-density lipoprotein receptor-related protein in liver. Proc Natl Acad Sci U S A (2012) 1.27
Central nervous system expression of IL-10 inhibits autoimmune encephalomyelitis. J Immunol (2001) 1.26
Interleukin-10 protects lipopolysaccharide-induced neurotoxicity in primary midbrain cultures by inhibiting the function of NADPH oxidase. J Pharmacol Exp Ther (2006) 1.25
Live imaging of neuroinflammation reveals sex and estrogen effects on astrocyte response to ischemic injury. Stroke (2008) 1.24
Extracellular heat shock protein 70: a critical component for motoneuron survival. J Neurosci (2005) 1.23
Circulating levels of tumour necrosis factor-alpha and its soluble receptors are increased in the blood of patients with amyotrophic lateral sclerosis. Neurosci Lett (2000) 1.21
Localization of a toxic form of superoxide dismutase 1 protein to pathologically affected tissues in familial ALS. Proc Natl Acad Sci U S A (2012) 1.17
Absence of tumor necrosis factor-alpha does not affect motor neuron disease caused by superoxide dismutase 1 mutations. J Neurosci (2006) 1.15
Live imaging of amyotrophic lateral sclerosis pathogenesis: disease onset is characterized by marked induction of GFAP in Schwann cells. Glia (2009) 1.12
Protective effects of heat shock protein 27 in a model of ALS occur in the early stages of disease progression. Neurobiol Dis (2007) 1.11
Neuroprotective effects of interleukin-10 following excitotoxic spinal cord injury. Exp Neurol (1999) 1.10
Local and systemic GM-CSF increase in Alzheimer's disease and vascular dementia. Acta Neurol Scand (2001) 1.10
Induction of proinflammatory molecules in mice with amyotrophic lateral sclerosis: no requirement for proapoptotic interleukin-1beta in neurodegeneration. Ann Neurol (2001) 1.08
Regulatory T lymphocytes from ALS mice suppress microglia and effector T lymphocytes through different cytokine-mediated mechanisms. Neurobiol Dis (2012) 1.07
Withaferin A inhibits tumor necrosis factor-alpha-induced expression of cell adhesion molecules by inactivation of Akt and NF-kappaB in human pulmonary epithelial cells. Int Immunopharmacol (2009) 1.06
Cerebrospinal fluid interleukin 6 in amyotrophic lateral sclerosis: immunological parameter and comparison with inflammatory and non-inflammatory central nervous system diseases. J Neurol Sci (1998) 1.06
GM-CSF increases LPS-induced production of proinflammatory mediators via upregulation of TLR4 and CD14 in murine microglia. J Neuroinflammation (2012) 1.04
Characterization of early pathogenesis in the SOD1(G93A) mouse model of ALS: part II, results and discussion. Brain Behav (2013) 1.03
Hsp27 and Hsp70 administered in combination have a potent protective effect against FALS-associated SOD1-mutant-induced cell death in mammalian neuronal cells. Brain Res Mol Brain Res (2004) 1.02
Transduced human PEP-1-heat shock protein 27 efficiently protects against brain ischemic insult. FEBS J (2008) 0.99
Real-time imaging of astrocyte response to quantum dots: in vivo screening model system for biocompatibility of nanoparticles. Nano Lett (2007) 0.99
Protein aggregation and defective RNA metabolism as mechanisms for motor neuron damage. CNS Neurol Disord Drug Targets (2010) 0.98
Decrease of Hsp25 protein expression precedes degeneration of motoneurons in ALS-SOD1 mice. Eur J Neurosci (2004) 0.97
The small heat shock proteins αB-crystallin and Hsp27 suppress SOD1 aggregation in vitro. Cell Stress Chaperones (2012) 0.95
Withaferin A inhibits pro-inflammatory cytokine-induced damage to islets in culture and following transplantation. Diabetologia (2013) 0.93
Thymic involution, a co-morbidity factor in amyotrophic lateral sclerosis. J Cell Mol Med (2010) 0.91
Characterization of early pathogenesis in the SOD1(G93A) mouse model of ALS: part I, background and methods. Brain Behav (2013) 0.91
Over-expression of Hsp27 does not influence disease in the mutant SOD1(G93A) mouse model of amyotrophic lateral sclerosis. J Neurochem (2008) 0.91
Heat shock protein 27 rescues motor neurons following nerve injury and preserves muscle function. Exp Neurol (2006) 0.90
Amyotrophic lateral sclerosis and excitotoxicity: from pathological mechanism to therapeutic target. CNS Neurol Disord Drug Targets (2010) 0.89
Myeloid-derived suppressor cell function is reduced by Withaferin A, a potent and abundant component of Withania somnifera root extract. Cancer Immunol Immunother (2013) 0.89
Increased IL-13-producing T cells in ALS: positive correlations with disease severity and progression rate. J Neuroimmunol (2006) 0.89
Withaferin A down-regulates lipopolysaccharide-induced cyclooxygenase-2 expression and PGE2 production through the inhibition of STAT1/3 activation in microglial cells. Int Immunopharmacol (2011) 0.88
Inhibition of monosodium urate crystal-induced inflammation by withaferin A. J Pharm Pharm Sci (2008) 0.87
Pathogenic mechanisms in familial amyotrophic lateral sclerosis due to mutation of Cu, Zn superoxide dismutase. Pathol Biol (Paris) (1996) 0.86
Lumbar motor neuron size and number is affected by age in male F344 rats. Mech Ageing Dev (1998) 0.85
Adeno-associated virus-mediated delivery of a recombinant single-chain antibody against misfolded superoxide dismutase for treatment of amyotrophic lateral sclerosis. Mol Ther (2013) 0.85
Withaferin A induces proteasome inhibition, endoplasmic reticulum stress, the heat shock response and acquisition of thermotolerance. PLoS One (2012) 0.85
Mitochondrial disfunction as a cause of ALS. Arch Ital Biol (2011) 0.82
Neuronal injury marker ATF-3 is induced in primary afferent neurons of monoarthritic rats. Neurosignals (2011) 0.82
Activation transcription factor-3 activation and the development of spinal cord degeneration in a rat model of amyotrophic lateral sclerosis. Neuroscience (2010) 0.81
Model system for live imaging of neuronal responses to injury and repair. Mol Imaging (2011) 0.80
Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron (2006) 6.38
Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS. Nat Neurosci (2010) 4.25
Selective ablation of proliferating microglial cells exacerbates ischemic injury in the brain. J Neurosci (2007) 3.93
Chromogranin-mediated secretion of mutant superoxide dismutase proteins linked to amyotrophic lateral sclerosis. Nat Neurosci (2005) 3.69
Innate immunity: the missing link in neuroprotection and neurodegeneration? Nat Rev Neurosci (2002) 2.97
Control of dendritic cell cross-presentation by the major histocompatibility complex class I cytoplasmic domain. Nat Immunol (2003) 2.27
Exacerbation of motor neuron disease by chronic stimulation of innate immunity in a mouse model of amyotrophic lateral sclerosis. J Neurosci (2004) 2.21
A NUDEL-dependent mechanism of neurofilament assembly regulates the integrity of CNS neurons. Nat Cell Biol (2004) 2.06
Axonal transport deficits and neurodegenerative diseases. Nat Rev Neurosci (2013) 2.05
Wild-type superoxide dismutase acquires binding and toxic properties of ALS-linked mutant forms through oxidation. J Neurochem (2007) 1.95
Neuroprotection through excitability and mTOR required in ALS motoneurons to delay disease and extend survival. Neuron (2013) 1.87
Microglial response to gold nanoparticles. ACS Nano (2010) 1.86
Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis (2002) 1.81
Giant axonal neuropathy-associated gigaxonin mutations impair intermediate filament protein degradation. J Clin Invest (2013) 1.79
Therapeutic effects of immunization with mutant superoxide dismutase in mice models of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A (2007) 1.73
Functions of intermediate filaments in neuronal development and disease. J Neurobiol (2004) 1.63
Extracellular mutant SOD1 induces microglial-mediated motoneuron injury. Glia (2010) 1.54
Requirement of myeloid cells for axon regeneration. J Neurosci (2008) 1.52
Ceruloplasmin regulates iron levels in the CNS and prevents free radical injury. J Neurosci (2002) 1.52
Efficient three-drug cocktail for disease induced by mutant superoxide dismutase. Ann Neurol (2003) 1.50
Intracerebroventricular infusion of monoclonal antibody or its derived Fab fragment against misfolded forms of SOD1 mutant delays mortality in a mouse model of ALS. J Neurochem (2010) 1.47
Deregulation of TDP-43 in amyotrophic lateral sclerosis triggers nuclear factor κB-mediated pathogenic pathways. J Exp Med (2011) 1.46
Breast-conserving treatment with or without radiotherapy in ductal carcinoma In Situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial. J Clin Oncol (2013) 1.34
Pathological hallmarks of amyotrophic lateral sclerosis/frontotemporal lobar degeneration in transgenic mice produced with TDP-43 genomic fragments. Brain (2011) 1.33
Alpha-internexin is structurally and functionally associated with the neurofilament triplet proteins in the mature CNS. J Neurosci (2006) 1.33
Ablation of proliferating microglia does not affect motor neuron degeneration in amyotrophic lateral sclerosis caused by mutant superoxide dismutase. J Neurosci (2008) 1.27
Live imaging of neuroinflammation reveals sex and estrogen effects on astrocyte response to ischemic injury. Stroke (2008) 1.24
Myosin Va binding to neurofilaments is essential for correct myosin Va distribution and transport and neurofilament density. J Cell Biol (2002) 1.20
Cell cycle regulators in the neuronal death pathway of amyotrophic lateral sclerosis caused by mutant superoxide dismutase 1. J Neurosci (2003) 1.19
Modest loss of peripheral axons, muscle atrophy and formation of brain inclusions in mice with targeted deletion of gigaxonin exon 1. J Neurochem (2008) 1.18
Increased glioma growth in mice depleted of macrophages. Cancer Res (2007) 1.18
Localization of a toxic form of superoxide dismutase 1 protein to pathologically affected tissues in familial ALS. Proc Natl Acad Sci U S A (2012) 1.17
Galectin-3 is required for resident microglia activation and proliferation in response to ischemic injury. J Neurosci (2012) 1.16
Absence of tumor necrosis factor-alpha does not affect motor neuron disease caused by superoxide dismutase 1 mutations. J Neurosci (2006) 1.15
Live imaging of amyotrophic lateral sclerosis pathogenesis: disease onset is characterized by marked induction of GFAP in Schwann cells. Glia (2009) 1.12
Transgenic mouse models of amyotrophic lateral sclerosis. Biochim Biophys Acta (2006) 1.11
The endoplasmic reticulum-Golgi pathway is a target for translocation and aggregation of mutant superoxide dismutase linked to ALS. FASEB J (2008) 1.10
New movements in neurofilament transport, turnover and disease. Exp Cell Res (2007) 1.09
A frameshift deletion in peripherin gene associated with amyotrophic lateral sclerosis. J Biol Chem (2004) 1.08
Misfolded SOD1 associated with motor neuron mitochondria alters mitochondrial shape and distribution prior to clinical onset. PLoS One (2011) 1.07
Treatment with minocycline after disease onset alters astrocyte reactivity and increases microgliosis in SOD1 mutant mice. Exp Neurol (2010) 1.05
Neuronal MEK is important for normal fear conditioning in mice. J Neurosci Res (2004) 1.05
Preoperative chemotherapy is safe in early breast cancer, even after 10 years of follow-up; clinical and translational results from the EORTC trial 10902. Breast Cancer Res Treat (2008) 1.01
Conditional NF-L transgene expression in mice for in vivo analysis of turnover and transport rate of neurofilaments. J Neurosci (2007) 1.01
Chromogranin B P413L variant as risk factor and modifier of disease onset for amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A (2009) 1.01
Differential neuroprotective effects of a minocycline-based drug cocktail in transient and permanent focal cerebral ischemia. Exp Neurol (2007) 1.00
Induction of protective immunity by vaccination with wild-type apo superoxide dismutase 1 in mutant SOD1 transgenic mice. J Neuropathol Exp Neurol (2010) 1.00
Disruption of neurofilament network with aggregation of light neurofilament protein: a common pathway leading to motor neuron degeneration due to Charcot-Marie-Tooth disease-linked mutations in NFL and HSPB1. Hum Mol Genet (2007) 1.00
Real-time imaging of astrocyte response to quantum dots: in vivo screening model system for biocompatibility of nanoparticles. Nano Lett (2007) 0.99
Macrophage colony stimulating factor (M-CSF) exacerbates ALS disease in a mouse model through altered responses of microglia expressing mutant superoxide dismutase. Exp Neurol (2009) 0.98
Brain-derived neurotrophic factor promotes vasculature-associated migration of neuronal precursors toward the ischemic striatum. PLoS One (2013) 0.97
Toll-like receptor 2 deficiency leads to delayed exacerbation of ischemic injury. J Neuroinflammation (2012) 0.96
Therapeutic immunization with a glatiramer acetate derivative does not alter survival in G93A and G37R SOD1 mouse models of familial ALS. Neurobiol Dis (2006) 0.96
Mitochondrial damage revealed by immunoselection for ALS-linked misfolded SOD1. Hum Mol Genet (2013) 0.96
ALS pathogenesis: recent insights from genetics and mouse models. Prog Neuropsychopharmacol Biol Psychiatry (2010) 0.95
Reversal of neuropathy phenotypes in conditional mouse model of Charcot-Marie-Tooth disease type 2E. Hum Mol Genet (2010) 0.95
Neurofilament transport in vivo minimally requires hetero-oligomer formation. J Neurosci (2003) 0.95
A neurotoxic peripherin splice variant in a mouse model of ALS. J Cell Biol (2003) 0.95
Peripherin is a subunit of peripheral nerve neurofilaments: implications for differential vulnerability of CNS and peripheral nervous system axons. J Neurosci (2012) 0.95
Involvement of TLR2 in recognition of acute gammaherpesvirus-68 infection. PLoS One (2010) 0.93
Mouse model for ablation of proliferating microglia in acute CNS injuries. Glia (2006) 0.93
PCSK9 reduces the protein levels of the LDL receptor in mouse brain during development and after ischemic stroke. J Lipid Res (2011) 0.93
Accumulation of dietary docosahexaenoic acid in the brain attenuates acute immune response and development of postischemic neuronal damage. Stroke (2011) 0.91
Ablation of proliferating cells in the CNS exacerbates motor neuron disease caused by mutant superoxide dismutase. PLoS One (2012) 0.90
Mouse model of intraluminal MCAO: cerebral infarct evaluation by cresyl violet staining. J Vis Exp (2012) 0.90
Normal role of the low-molecular-weight neurofilament protein in mitochondrial dynamics and disruption in Charcot-Marie-Tooth disease. FASEB J (2011) 0.90
Natural history of node-negative breast cancer: are conventional prognostic factors predictors of time to relapse? Breast (2002) 0.89
Real-time imaging reveals defects of fast axonal transport induced by disorganization of intermediate filaments. FASEB J (2009) 0.89
The high and middle molecular weight neurofilament subunits regulate the association of neurofilaments with kinesin: inhibition by phosphorylation of the high molecular weight subunit. Brain Res Mol Brain Res (2005) 0.89
Cyclin-dependent kinase 5 in amyotrophic lateral sclerosis. Neurosignals (2003) 0.89
Defective axonal transport of neurofilament proteins in neurons overexpressing peripherin. J Neurochem (2006) 0.88
Induction of peripherin expression in subsets of brain neurons after lesion injury or cerebral ischemia. Brain Res (2002) 0.88
Aggregate formation and phosphorylation of neurofilament-L Pro22 Charcot-Marie-Tooth disease mutants. Hum Mol Genet (2006) 0.88
Local electronic structure and Fano interference in tunneling into a Kondo hole system. Phys Rev Lett (2012) 0.87
ALS: astrocytes move in as deadly neighbors. Nat Neurosci (2007) 0.87
Neuronal expression of peripherin, a type III intermediate filament protein, in the mouse hindbrain. Histochem Cell Biol (2007) 0.87
Peripherin-mediated death of motor neurons rescued by overexpression of neurofilament NF-H proteins. J Neurochem (2003) 0.87
Wild-type human SOD1 overexpression does not accelerate motor neuron disease in mice expressing murine Sod1 G86R. Neurobiol Dis (2010) 0.86
Altered immune response to CNS viral infection in mice with a conditional knock-down of macrophage-lineage cells. Glia (2006) 0.86
Real-time imaging after cerebral ischemia: model systems for visualization of inflammation and neuronal repair. Methods Enzymol (2012) 0.85
Pathways to motor neuron degeneration in transgenic mouse models. Biochimie (2002) 0.85
The type III neurofilament peripherin is expressed in the tuberomammillary neurons of the mouse. BMC Neurosci (2008) 0.85
Als2 mRNA splicing variants detected in KO mice rescue severe motor dysfunction phenotype in Als2 knock-down zebrafish. Hum Mol Genet (2008) 0.85
The role of the MYD88-dependent pathway in MPTP-induced brain dopaminergic degeneration. J Neuroinflammation (2011) 0.84
Normal dendritic arborization in spinal motoneurons requires neurofilament subunit L. J Comp Neurol (2002) 0.84
Neuronal over-expression of chromogranin A accelerates disease onset in a mouse model of ALS. J Neurochem (2010) 0.84
Alsin is partially associated with centrosome in human cells. Biochim Biophys Acta (2005) 0.83
Sensorimotor and cognitive function of a NEFL(P22S) mutant model of Charcot-Marie-Tooth disease type 2E. Behav Brain Res (2010) 0.83
Type III intermediate filament peripherin inhibits neuritogenesis in type II spiral ganglion neurons in vitro. Neurosci Lett (2010) 0.81
Abnormal regenerative responses and impaired axonal outgrowth after nerve crush in TDP-43 transgenic mouse models of amyotrophic lateral sclerosis. J Neurosci (2012) 0.81
Cytoskeletal defects in amyotrophic lateral sclerosis (motor neuron disease). Novartis Found Symp (2005) 0.81
Lipopolysaccharide-QD micelles induce marked induction of TLR2 and lipid droplet accumulation in olfactory bulb microglia. Mol Pharm (2010) 0.81